A broad label extension has been approved by the European Commission for bevacizumab [Avastin; Roche].

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1624, 2008-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Roche's bevacizumab [Avastin] has been approved as a first-line treatment for advanced renal cell cancer in the EU

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite

Bevacizumab [Avastin; Roche] has been launched in the UK as a first-line treatment for metastatic breast cancer

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

The Swiss health authority, Swissmedic, has approved Roche's bevacizumab

Inpharma, Vol. 1, Iss. 1473, 2005-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Rituximab [`Rituxan'; Nippon Roche] has been approved in Japan

Inpharma, Vol. 1, Iss. 1297, 2001-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Levetiracetam [Keppra; UCB] has been approved by the European Commission for the treatment of partial onset seizures

Inpharma, Vol. 1, Iss. 1552, 2006-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite